Chapter Six - Trials, Patents, and Profit Motives

CHAPTER SIX

Trials, Patents, and Profit Motives

IF CANCER IS a battlefield, then clinical trials are the arms race and patents are the prize.

This is where science stops being a neutral pursuit of truth and becomes a game of leverage, delay, and ROI. Because for pharmaceutical companies, the goal isn’t just to find something that works.

The goal is to find something exclusive.
Something you can own.

Let’s talk trials.

To get a drug approved in the United States, it has to go through phases.
Phase I tests safety.
Phase II tests effectiveness.
Phase III scales it up to see if the results hold.
Each phase costs money. Each phase takes time. And the longer it takes, the more expensive it gets. We’re talking hundreds of millions to billions of dollars, per drug, just to reach the finish line.

That’s assuming the drug even makes it.

Most don’t.

Which means the handful that do need to cover not only their own cost, but the cost of every other failure too. That’s the justification for the price tags. That’s how they explain $12,000-a-month chemo.

But here’s the other half of the story:

Trials aren’t just about science.
They’re about strategy.

You can shape outcomes of trial results based on what you measure. You can make your drug look better by testing it against a weaker comparator. You can set endpoints that don’t reflect actual survival or quality of life, just whether a tumor shrank by 20% over twelve weeks.

That’s a real metric. It’s called progression-free survival. And it’s used all the time to fast-track drugs that may or may not actually help patients live longer.

You can also select trial participants strategically. Choose healthier patients. Filter out complex cases. Run the numbers in a way that gives you the story you need.

Because that’s what trials are now. Not just tests of biology, but pitches to regulators, insurers, and investors.

Now patents.

A drug patent gives you exclusive rights to sell that compound for a fixed period of time, usually 20 years from the date of filing. But most drugs take a decade just to get approved. So companies find ways to extend those patents.

They tweak the formulation slightly.
They develop “extended-release” versions.
They add a delivery mechanism.
They file follow-up patents.
It’s called evergreening, keeping the clock running.

Why? Because once the patent expires, generics enter the market. Prices drop. Profits vanish.

So there’s a race. Not just to invent, but to protect.
Because without a patent, your drug is almost impossible to finance.

That means:

If a scientist finds a promising compound but can’t patent it?
No one funds the trial.
No one runs the studies.
It dies on the lab bench.

Not because it didn’t work.
But because it didn’t make sense on paper.

And here’s the kicker.

The NIH, your tax dollars, funds a huge portion of the basic research behind cancer drugs.
Pharma comes in later, buys up the science, polishes it, runs trials, locks it down, and sells it back to you for a small fortune.

The public pays twice.
Once to discover the treatment.
Then again to afford it.

This doesn’t mean all drugs are scams.
There are brilliant treatments out there.
Lives saved. Time bought. Miracles delivered.

But the system they’re embedded in?
It’s not built to cure.

It’s built to monetize the long road.
Delay, patent, prescribe, repeat.

The bigger the fear, the bigger the market.
And cancer is the biggest fear of all.

So ask yourself:

If a miracle cure were found tomorrow, one that was simple, unpatentable, and cheap to produce, would it ever see the light of day?

Who would fund it?
Who would manufacture it?
Who would approve it?

And who would lose everything if it worked?